Liminatus Pharma LIMN 深 滬
已收盤 06-05 16:00:00 美东时间
0.1422
-0.009
-5.95%
華盛通- 最 高0.1548
- 今 開0.1512
- 成交量 280.15万股
- 最 低 0.1359
- 昨 收 0.1512
- 總市值 638.16万
- 52周最高 33.66
- 市盈率 靜 --
- 換手率 6.24%
- 52周最低 0.132
- 委 比 -79.49%
- 總股本 4487.76万
- 歷史最高 33.66
- 量 比 0.42
- 振 幅 12.50%
- 歷史最低 0.132
- 每 手 1
- 風險率 4.80%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Liminatus Pharma secures $1.9M cash via warrant exercises
Liminatus Pharma (LIMN) has entered into a warrant exercise agreement to exercise certain outstanding warrants to purchase an aggregate of 10.34M shares of common stock of the company for gross procee...
06-03 21:14
Liminatus Pharma Enters Warrant Exercise Agreement With Existing Investors To Purchase 10,344,000 Shares At $0.18 Per Share
In consideration for the immediate exercise of the Existing Warrants for cash, the exercising holders were issued new unregistered warrants to purchase an aggregate of 20,688,000 million shares of common stock (the "New
06-03 20:33
超20亿元！一细胞治疗公司被收购
（来源：细胞与基因治疗领域） 近期，美国癌症免疫治疗公司Liminatus Pharma宣布，已达成最终协议，将以3.2亿美元（约合人民币21.6亿元）收购细...
05-31 15:17
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Akari Therapeutics (NASDAQ:AKTX) stock increased by 40.3% to $7.21 dur...
05-22 05:06
Liminatus Pharma Announces Nasdaq Delisting Notification
Liminatus Pharma, Inc. received a delisting notice from Nasdaq as it failed to meet the $50 million market value of listed securities and $15 million market value of publicly held shares requirements. The company had 180 days to regain compliance but did not meet the criteria by May 18, 2026. Trading of its securities will be suspended on May 29, 2026, unless an appeal is filed by May 27, 2026. The company intends to request an appeal to delay de...
05-22 00:28
Liminatus Pharma Enters Merger Agreement With InnocsAI On May 17, 2026; InnocsAI Members To Receive 1.6B Shares At $0.20 Per Share And 20% Contingent Value Rights
On May 17, 2026, Liminatus Pharma, Inc. (the "Company") entered into a Merger Agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with InnocsAI LLC,
05-21 05:12
Why NN Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
NN Inc. (NNBR) rose in pre-market trading after announcing expected sales growth and raising full-year guidance. Other gainers include NICM, AGAE, IMMP, LIMN, CIIT, MLSS, LAES, GBR, and STNE. Losers include SNAL, MIMI, ARAI, and SURG.
04-15 16:51
Liminatus Intends To Start Phase 1 Clinical Study Of CD47-Blocking Monoclonal Antibody
Liminatus today announced plans to initiate a Phase 1 clinical trial evaluating IBA101, a next-generation CD47-blocking monoclonal antibody designed to engage innate immune pathways and complement established
03-17 20:14
Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody
Liminatus announced plans to initiate a Phase 1 clinical trial for IBA101, a next-generation CD47-blocking monoclonal antibody designed to enhance immune system engagement against cancer cells. The trial will evaluate the safety, tolerability, and effectiveness of IBA101, both as monotherapy and in combination with PD-1/PD-L1 inhibitors, initially focusing on lung cancer. The study, led by Dr. Se-Hoon Lee, aims to provide early insights into the ...
03-17 12:08
Gold Down 3%; Medtronic Earnings Top Views
U.S. stocks traded mostly lower midway through trading, with the Nasdaq Composi...
02-18 01:14
